Clinical Trial Update: A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic and excretion study of 14C-GSK2248761 in healthy adults was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• GSK2248761 (14C-labeled) (GSK2248761)

Snippet

Sponsor: ViiV Healthcare | Conditions: Infection, Human Immunodeficiency Virus | Phase 1 | Status: WITHDRAWN